NEJM publishes long-term results of Gleevec for 1,106 patients worldwide

Scemblix improves MMR rates for Ph+ CML-CP in phase III trial

Novartis presented positive results from the pivotal phase III ASC4FIRST trial as a late-breaking abstract at the 2024 American Society of Clinical Oncology meeting.

May 31, 2024

Vol.50 No.22

Drugs & Targets

FDA approves Bosulif for pediatric patients with CML

FDA has approved Bosulif (bosutinib) for pediatric patients ages one year and older with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) that is newly diagnosed or resistant or intolerant (R/I) to prior therapy.

September 29, 2023

Vol.49 No.36

Drugs & Targets

EU approval granted to Novartis SCEMBLIX for CML

The European Commission has approved Scemblix (asciminib) for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with two or more tyrosine kinase inhibitors.

September 09, 2022

Vol.48 No.32

Cancer History Project Conversation with The Cancer Letter

In 1998, a CML patient was out of options. Then she chanced into a treatment–Gleevec

When Judy Orem learned of her chronic myeloid leukemia diagnosis in 1995, she chose interferon over a treatment that seemed more risky—a bone marrow transplant.

June 03, 2022

Vol.48 No.22

By Deborah Doroshow and Alexandria Carolan

NEJM publishes long-term results of Gleevec for 1,106 patients worldwide

YOU MAY BE INTERESTED IN

Scemblix improves MMR rates for Ph+ CML-CP in phase III trial

FDA approves Bosulif for pediatric patients with CML

EU approval granted to Novartis SCEMBLIX for CML

In 1998, a CML patient was out of options. Then she chanced into a treatment–Gleevec

Renew today!

Subscriber content

Login